Ligand CEO Says Some Zoma Assets Were 'Underwritten, Frankly, To Zero' — And Are Now Looking Better

Todd Davis found "option value" in the $730 million Zoma portfolio but left earlier earnings targets unchanged.

Share
Ligand CEO Says Some Zoma Assets Were 'Underwritten, Frankly, To Zero' — And Are Now Looking Better

Ligand Pharmaceuticals CEO Todd Davis said on the company's third-quarter earnings call Thursday that some assets bought in the $730 million Zoma deal were valued at nothing and are now producing positive news. Ligand, a royalty company that buys stakes in drugs developed by other firms, left its earlier Zoma earnings targets unchanged.

Hidden gems in a triaged portfolio

A Craig-Hallum analyst asked whether deeper digging had turned up assets beyond the handful Ligand originally priced. Davis said valuing a portfolio that size meant triaging, so the original valuation covered only a "small subset" of Zoma's assets.

Since then, he said, there has been news flow on things Ligand had "underwritten, frankly, to zero that are developing quite nicely and have positive information." He cited "option value" in assets such as the Resolute assets and Biloxibat, and said Ligand can supply follow-on capital to support some of those companies.

Davis called Zoma the largest transaction in Ligand's history. It closed July 14.

Earnings targets hold for now

The analyst noted that Ligand had earlier guided to 50 cents of Zoma contribution to earnings this year and $1.50 next year. Davis answered, "no changes to that." Chief Financial Officer Octavio Espinoza said any update to next year's contribution would come at the investor day on December 8.

Espinoza also said the acquired business ran cash operating costs above $25 million. Ligand had targeted about $5 million a year after the deal, and he now expects it to be just under $5 million.

The quarter behind the call

Royalty revenue rose 51% from a year earlier to $70.3 million, with Zoma's assets adding $12.3 million in the roughly 11 weeks since closing. Adjusted earnings were $2.67 a share, against $3.09 a year earlier, which included $24.5 million of one-time license income. Ligand reported a GAAP net loss of $1.43 a share.

The company raised its 2026 adjusted EPS guidance to $9.50 to $9.75 from $9.00 to $9.50, and reaffirmed its revenue guidance. Ligand says it is entering a catalyst-rich stretch, with up to seven pivotal readouts through 2027, five from Zoma. The stock's market value was $6.4 billion in Thursday morning trading.

Ligand will update its five-year outlook and the Zoma contribution at its investor day on December 8.

Sources

More on Ligand Pharmaceuticals

All Ligand Pharmaceuticals (LGND) coverage →